RainDance Technologies Announces First Commercial Shipment of RDT 1000, Sequence Enrichment Solution
Delivery to Ontario Institute for Cancer Research
LEXINGTON, MASSACHUSETTS, U.S.A., March 26, 2009 -- RainDance Technologies, Inc., a provider of innovative microdroplet-based solutions for human health and disease research, today announced the first commercial shipment of its RDT 1000 and Sequence Enrichment Solution. The shipment will be delivered to the Ontario Institute for Cancer Research in Canada (OICR), a new, innovative institute dedicated to research in the prevention, early detection, diagnosis and treatment of cancer.
OICR will use the RainDance solution - consisting of a RDT 1000, consumables kits, custom PCR primer libraries, and expert training - in its programs involving the discovery and validation of DNA sequence variants associated with cancers. The solution is designed to increase quality and efficiency of performing targeted sequencing on large sample numbers.
"We are looking forward to implementing the RainDance platform at OICR - and to the benefits that the RainDance solution will bring to our programs," said John McPherson, Director of OICR's Cancer Genomics Program. "We expect the RainDance solution to become a critical element in accelerating the research phase of our studies that will ultimately result in our understanding of cancer."
"The shipment to OICR represents a major milestone that exemplifies the power of the RainStorm(TM) microdroplet-based platform to those driving innovation in human health and disease research," said Chris McNary, President and Chief Executive Officer of RainDance Technologies. "First, leading genome centers participating in the company's Early Access Partner program have experienced the value of the RainDance solution. Now, our commercial platform is shipping and gaining acceptance in the rapidly growing sequence enrichment segment of the next-generation sequencing market."
The RDT 1000 and Sequence Enrichment Solution utilize RainDance's breakthrough RainStorm(TM) microdroplet-based technology platform. The simplicity and speed of the technology are designed to maximize the efficiency of next-generation DNA sequencing workflows. The RDT 1000 generates picoliter volume PCR reactions at the rate of 10 million discrete reactions per hour. The high-speed sample processing is further enhanced by the fact that the Sequence Enrichment Solution utilizes a library of PCR primers in droplets enabling the amplification of hundreds to thousands of genomic loci in a single tube. The RainStorm format avoids the limitations of traditional multiplex hybridization and amplification technologies. RainDance's solution minimizes process-induced bias or error and requires only a few micrograms of genomic DNA.
"All of us at RainDance are grateful for the opportunity to support OICR -- one of the world's leading centers of cancer research -- in its mission to advance human health," McNary said.
The commercial version of the Sequence Enrichment Solution is now being shipped in North America and will soon be available for shipment to Europe. For more information, contact firstname.lastname@example.org, call 781-861-6300, or visit the company's website at www.RainDancetech.com.
About RainDance Technologies, Inc.
RainDance Technologies Inc. is a provider of innovative microdroplet-based solutions for human health and disease research. The speed and simplicity of the company's exciting new technology platform enable researchers to design experiments in ways that were previously unaffordable or unimaginable. The company's RainStorm(TM) technology produces picoliter-volume droplets at a rate of 10 million per hour. Each droplet is the functional equivalent of an individual test tube and can contain a single molecule, reaction, or cell. This versatile technology can adapt proven assays for high-speed workflows with minimized process-induced bias or error.
RainDance's initial application will focus on the targeted sequencing of the human genome â" one of the fastest-growing segments of the $1 billion DNA sequencing market. This application will enable the high-resolution analysis of genetic variation between individuals and populations at a level unmatched by current methodology.
RainDance was founded in 2004 by scientists from Harvard University, the Medical Research Centre in Cambridge, England and the ESPCI in Paris.
For more information, please visit www.RainDancetech.com .
MassBio Membership gives you:
Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members.
Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.
MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.
Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.
Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.
Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!
Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.